Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)

Inclusion Criteria:

1. Treatment-naïve patients with newly diagnosed nodal T-cell lymphoma with T-follicularhelper (TFH) phenotype as determined by the following 2016 WHO diagnostic criteria:

• Angioimmunoblastic T-cell lymphoma
• Follicular helper T-cell lymphoma
• Peripheral T-cell lymphoma with follicular helper T-cell type

2. 20 to 85 years of age at diagnosis
3. ECOG performance status 0-2
4. Cardiac function suitable for chemotherapy: LVEF ≥45% on echocardiography or MUGA
5. Appropriate renal function: Serum Cr ≤2.0mg/dL or eGFR ≥ 30mL/min according to theCockroft-Gault formula
6. Appropriate hepatic function: ALT ≤2.5x upper limit of normal (ULN) (or ≤5x ULN in thepresence of liver involvement), total bilirubin ≤2x ULN (or ≤3x ULN in the presence ofliver involvement)
7. Appropriate hematologic findings: absolute neutrophil count (ANC) ≥1,500/μL, platelets ≥100,000/μL (or ANC ≥500/μL and platelets ≥50,000/ μL in the presence of bone marrowinvolvement)
8. Written informed consent to participate in the study
9. Capable of following the study visit schedule and other requirements in the protocol
10. For women of childbearing potential, a negative pregnancy test
11. Women of childbearing potential must use an effective method of contraception (i.e.,hormonal contraception, intrauterine device, diaphragm with spermicide, condom withspermicide, or abstinence) during the study period and for 3 months afterward. Men areto use an effective method of contraception during the study period and for 3 monthsafterward.
12. Life expectancy ≥90 days (3 months)
13. Hepatitis B or C infection: Hepatitis B carriers and subjects with inactive hepatitisC infection (normal levels of aminotransferases) are eligible if they takeprophylactic antiviral drugs

Exclusion Criteria:

1. Other subtypes of non-Hodgkin's lymphoma
2. History of chemotherapy for Hodgkin's or other non-Hodgkin's lymphoma in the last 5years
3. History of active cancer diagnosed within the last 3 years (with the exception ofcompletely resected non-melanoma skin cancer, papillary thyroid cancer, carcinoma insitu of cervical cancer or breast cancer, and localized prostate cancer)
4. Uncontrolled hepatitis B (with the exception of asymptomatic HBsAg-positive oranti-HBcAb-positive cases receiving antiviral prophylaxis such as entecavir ortenofovir)
5. History of chronic hepatitis C (with the exception of HCV IgG positive with a negativeHCV-RNA quantification)
6. History of human immunodeficiency virus (HIV) infection
7. Congestive heart failure (NYHA class ≥3)
8. Acute coronary syndrome (new-onset unstable angina or myocardial infarction) orventricular tachycardia within 6 months prior to study entry
9. History of major neurological or psychiatric illness, including dementia or epilepsy
10. Severe chronic obstructive pulmonary disease with hypoxemia
11. Cerebrovascular disease within 3 months prior to study entry (including transientcerebral ischemia)
12. Unresolved wounds, ulcers, or bone fractures
13. Uncontrolled active infections (viral, bacterial, or fungal infections)
14. Concurrent use of other experimental drugs under investigation
15. Known hypersensitivity to the investigational drugs
16. History of major surgery or serious trauma within 21 days prior to study treatment.Open biopsy within 7 days prior to study treatment
17. Male subjects who had not undergone a vasectomy and have a partner who plans to becomepregnant or are unable to use a medically acceptable method of contraception (partner's sterilization or intrauterine device placement, or barrier method combinedwith diaphragm or condom) during the subject's participation in the study
18. Pregnant or breastfeeding women or women of childbearing potential and men who are notwilling to use appropriate methods of contraception during the study
19. Previously treated for T-cell lymphoma with immunotherapy or chemotherapy, except forshort-term corticosteroids (for less than 8 days) prior to selection
20. Prior radiotherapy, except for those localized to a single lymph node
21. Central nervous system involvement
22. Contraindication to any of the drugs included in the chemotherapy
23. History of administration of doxorubicin at >200 mg/m²